Received by email:

File: '\\office\emailin\20220613 231241 Attachment Press Release June 14. 2022  Pascal.docx'










PASCAL BIOSCIENCES PLANS NEW DIRECTION TO INCLUDE CONTRACT RESEARCH

VANCOUVER, BRITISH COLUMBIA, June 14, 2022. Pascal Biosciences Inc. ("Pascal" or "the Company") (TSXV:PAS) (OTC:PSCBF)
---> (FSE: 6PB-FF) is announcing a renewed and expanded emphasis on the consulting and contract research component of the 
--->business. Pascal has previously had success by providing resources to other biotech companies. In particular, the Comp
--->any worked with SoRSE Technology last year, bringing over $600,000 into the company. Pascal scientists have, combined,
---> over 80 years of experience in biotechnology projects and have been involved in the discovery, preclinical, and clini
--->cal development of drugs approved by the FDA. Our intent is to leverage this expertise to provide consulting and resea
--->rch services to customers with projects primarily in the post-discovery to Phase I period of development.

"Drug development has long timelines and, unless new drug candidates are forthcoming, preclinical teams tend to become
---> redundant once a drug enters clinical studies."  stated CEO Dr. Brian Bapty. "By providing virtual preclinical servic
--->es, Pascal can provide the direction, experience, and facilities to efficiently support multiple preclinical programs.
--->" As with the SoRSE contract, Pascal will provide shared expertise and infrastructure so Biotech clients benefit from 
--->economies of scale while limiting fixed costs.

Pascal is in process of updating the website to reflect these changes. Pascal will continue development of internal pr
--->ograms notably, for Acute Lymphoblastic Leukemia which is funded by an NIH Grant, and glioblastoma which will be suppo
--->rted by funds from operations.   


ABOUT PASCAL BIOSCIENCES INC.

Pascal is a biotechnology company advancing innovative therapies for serious diseases. In addition to a targeted thera
--->py for Acute Lymphoblastic Leukemia, Pascal is developing cannabinoid-based treatments for cancer. These compounds inc
--->lude PAS-403, which is advancing towards clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-sti
--->mulatory cannabinoid to be used in combination with checkpoint inhibitor therapy to treat multiple cancers. The PAS-39
--->3 program was previously developed in collaboration with SoRSE Technology. PAS-393 also shows promise for treating Cov
--->id-19, and Pascal holds a patent for the use of cannabinoids in treatment of Covid-19. 

To learn more, visit: https://www.pascalbiosciences.com/. 

Company Contact:
Dr. Brian Bapty, CEO
Dr. Patrick W. Gray, Chairman 
invest@pascalbiosciences.com
Tel: 206-221-3443

Forward-Looking Statements 
DISCLAIMER
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securiti
--->es Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that 
--->may not be based on historical fact, including without limitation statements containing the words "believe", "may", "p
--->lan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking s
--->tatements or information involve known and unknown risks, uncertainties and other factors that may cause our actual re
--->sults, events or developments, or industry results, to be materially different from any future results, events or deve
--->lopments express or implied by such forward-looking statements or information. Such factors include, among others, our
---> stage of development, lack of any product revenues, additional capital requirements, risk associated with the complet
--->ion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectu
--->al property, dependence on collaborative partners and the prospects for negotiating additional corporate collaboration
--->s or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actu
--->al events or results expressed or implied by such forward-looking statements and information to differ materially from
---> any future events or results expressed or implied by such statements and information include, but are not limited to,
---> the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or futu
--->re products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; 
--->we may not be able to raise additional capital; we may not be successful in establishing additional corporate collabor
--->ations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products ma
--->y be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to
---> intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and oth
--->er factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com.
---> Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements
---> and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements a
--->nd information made herein are based on our current expectations and we undertake no obligation to revise or update su
--->ch forward- looking statements and information to reflect subsequent events or circumstances, except as required by la
--->w.

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the
---> TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"